Potential HCV Drug INX-189 Completes Initial Safety Trial
Share
Follow Us
The Editors at Hepatitis Central
September 3, 2010
INX-189, Inhibitex’s nucleotide polymerase inhibitor in development to fight chronic Hepatitis C, passes the first stage of human testing by demonstrating its safety.
Inhibitex Successfully Completes Phase 1a Trial of INX-189
Proof-of-Concept Trial in Patients with Chronic Hepatitis C Planned for Q4 2010
ATLANTA, Sep 01, 2010 (BUSINESS WIRE) — Inhibitex, Inc. announced today that it has successfully completed a Phase1a, first-in-man, single ascending dose trial of INX-189, its nucleotide polymerase inhibitor in development for the treatment of chronic hepatitis C (HCV) infections. In this trial, 42 healthy volunteers received either a single oral dose of INX-189, ranging from 3 mg to 100 mg, or placebo.
Continue reading this entire article:
http://www.marketwatch.com/story/inhibitex-successfully-completes-phase-1a-trial-of-inx-189-2010-09-01?reflink=MW_news_stmp
